This anti-aging stack combines three peptides that target different hallmarks of aging: epithalon addresses telomere attrition through telomerase activation, GHK-Cu modulates gene expression involved in tissue repair and antioxidant defense, and BPC-157 provides broad-spectrum cytoprotection and regeneration. Together, they represent a multi-pathway approach to supporting cellular health during aging.
The longevity peptide field is mechanistically diverse but evidence-thin. Epithalon has the most direct anti-aging mechanism (telomerase activation) with published Russian clinical data but limited Western validation. GHK-Cu has published human studies in dermatology and gene expression research identifying over 4,000 affected genes. BPC-157 has the broadest preclinical evidence base for tissue repair but no completed human trials. This stack is speculative — it combines plausible mechanisms without clinical proof that the combination extends healthspan or lifespan.
Important: No peptide or combination of peptides has been proven to reverse aging in humans. The concept of an anti-aging stack is based on mechanistic reasoning, not clinical trial evidence. This guide is for educational purposes only and does not constitute medical advice or endorse any specific longevity protocol.
GHK-Cu shifts gene expression toward a younger pattern — it may function as an endogenous anti-aging signal that the body produces less of over time.
The peptides
Why these work together
This stack targets three of the nine hallmarks of aging through independent pathways. Epithalon activates telomerase, which adds TTAGGG repeats to chromosome ends, counteracting the telomere shortening that occurs with each cell division. Critically short telomeres trigger cellular senescence or apoptosis — by maintaining telomere length, epithalon may extend the replicative capacity of cells. It also stimulates pineal melatonin production, which has independent antioxidant and circadian-regulatory functions that decline with age.
GHK-Cu operates through gene expression modulation rather than a single enzymatic target. Genome-wide studies have identified over 4,000 genes affected by GHK-Cu, with significant upregulation of DNA repair genes, antioxidant enzymes (SOD, glutathione pathways), and collagen synthesis genes, and downregulation of inflammatory and fibrotic genes. This broad transcriptomic effect is why GHK-Cu is sometimes described as a "reset" signal — it shifts gene expression toward a younger pattern. Its decline with age suggests it may function as an endogenous anti-aging signal that the body produces less of over time.
BPC-157 contributes through systemic tissue maintenance. Its activation of the FAK-paxillin pathway, nitric oxide modulation, and growth hormone receptor upregulation collectively support the body's ongoing repair and regeneration processes. While not targeting an aging hallmark directly, it addresses the functional consequences of aging — accumulated tissue damage, reduced healing capacity, and compromised tissue integrity — that degrade quality of life.
Suggested protocol
10-day epithalon course to stimulate telomerase activity. GHK-Cu topical continues as daily baseline. Run epithalon in isolation from other injectable cycles.
BPC-157 daily for systemic tissue repair plus GHK-Cu injectable cycles for deeper gene-expression modulation. GHK-Cu topical continues throughout.
BPC-157 break to prevent tolerance. GHK-Cu topical continues year-round as the constant baseline of this protocol.
Repeat the cycle year-round. Epithalon 2–3× per year (10-day courses). BPC-157 8 weeks on / 4 weeks off. GHK-Cu topical year-round, injectable in periodic cycles.
Safety considerations
Limited Western clinical data (Russian studies). Theoretical cancer concern from telomerase stimulation. Avoid with cancer history. Cycle-based use (not continuous).
Well-tolerated topically with decades of cosmetic use. Injectable has less safety data but considered low-risk. Minimal reported side effects.
Generally well-tolerated (nausea, headache). Angiogenic properties warrant caution with tumors. No completed human trials.
The combination of all three peptides has never been studied in clinical trials. Additive side effects, drug interactions, and long-term safety are unknown. Not appropriate for individuals with active or prior pancreatitis, MEN 2 syndrome, active cancer, or during pregnancy/breastfeeding. Physician supervision is essential.
Frequently asked questions
Individual peptides target specific hallmarks of aging — epithalon activates telomerase, GHK-Cu modulates age-related gene expression changes, BPC-157 supports tissue repair capacity. Whether these effects translate to measurable lifespan extension or healthspan improvement in humans is unproven. Mechanistic plausibility exists, but clinical proof is years or decades away. Treat anti-aging peptide use as speculative, not established medicine.
Biomarkers to track include telomere length (before and after epithalon cycles), inflammatory markers (hs-CRP, IL-6), skin elasticity and collagen density (for GHK-Cu), and general metabolic health markers. However, aging is a slow process, and meaningful changes in these biomarkers may take months to years. Subjective improvements in sleep quality, skin appearance, energy, and recovery are commonly reported but are not definitive evidence of anti-aging effects.
This is the central safety question for epithalon. Cancer cells reactivate telomerase to achieve immortality, so artificially stimulating telomerase in normal cells raises a theoretical cancer risk. Available epithalon studies have not shown increased cancer incidence, and some researchers argue that maintaining telomere length may actually reduce cancer risk by preventing the genomic instability that occurs when telomeres become critically short. However, long-term human safety data is insufficient to resolve this question definitively.
Yes, topical GHK-Cu is the most accessible and safest entry point for this stack. Multiple human studies have demonstrated skin improvements with topical GHK-Cu serums. The gene expression modulation effects have been primarily studied with systemic (injectable) GHK-Cu, so topical use may have primarily local (skin) rather than systemic anti-aging effects. Many users start with topical GHK-Cu and add injectable protocols later.
Anti-aging protocols are inherently long-term. Epithalon is used in periodic cycles (10-day courses, 2-3 times per year) rather than continuously. GHK-Cu topical use is typically ongoing. BPC-157 cycling varies by protocol. Most longevity-focused practitioners recommend a minimum commitment of 1-2 years with periodic biomarker tracking before drawing conclusions about efficacy. This is a marathon, not a sprint.